Therapy Areas: Infectious Diseases
Enesi Pharma & Public Health England partnership plans needle-free solid-dose vaccine against infectious and other select diseases
1 October 2018 -

Pharmaceutical company Enesi Pharma reported on Monday the launch of a research and development collaboration for novel needle-free solid-dose vaccine for emergent threat pathogens with Public Health England (PHE), an executive agency of the UK Government's Department of Health and Social Care.

PHE will reportedly develop and evaluate a novel solid-dose formulation of a number of its proprietary vaccine candidates including Anthrax recombinant Protective Antigen (rPA) and Crimean-Congo Haemorrhagic Fever (CCHF) for delivery using Enesi Pharma's ImplaVax needle-free technology.

In conjunction, the pre-clinical testing of a range of ImplaVax enabled vaccines in animal models has evidenced regimen sparing and a reduced time to achieve threshold immunity against comparative conventional liquid vaccines administered using a needle and syringe.

The ImplaVax's enabled vaccines saves time and money, allowing more patients to be vaccinated more quickly from a fixed available production volume, potentially expanding coverage, preparedness and emergency response. The current vaccination schedules of many vaccines require multiple doses.

An ImplaVax-enabled vaccine can enhance vaccination programmes for military and other at-risk personnel, provide a rapidly deployable therapeutic option for individuals who have been exposed to the target infectious disease, benefit from extended thermal stability, reduce the end to end cold chain logistical challenges, cost as well as greatly assist in optimising the cost effectiveness of the national strategic stockpile.



Related Headlines